Population pharmacokinetics and exposure–response modeling and simulation for evolocumab in healthy volunteers and patients with hypercholesterolemia

Evolocumab, a novel human monoclonal antibody, inhibits proprotein convertase subtilisin/kexin type 9, a protein that targets low-density lipoprotein-cholesterol (LDL-C) receptors for the treatment of hyperlipidemia. The primary objective of this analysis was to characterize the population pharmacok...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Pharmacokinet Pharmacodyn
Главные авторы: Kuchimanchi, Mita, Grover, Anita, Emery, Maurice G., Somaratne, Ransi, Wasserman, Scott M., Gibbs, John P., Doshi, Sameer
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2018
Предметы:
Original Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5953983/
https://ncbi.nlm.nih.gov/pubmed/29736889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10928-018-9592-y
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы